Literature DB >> 11897535

Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?

Margherita Capasso1, Filomena Torrieri, Antonio Di Muzio, Maria Vittoria De Angelis, Alessandra Lugaresi, Antonino Uncini.   

Abstract

OBJECTIVES: Patients with polyneuropathy and antibodies to myelin-associated glycoprotein (MAG) and sulphated glucuronyl paragloboside (SGPG) differ from chronic inflammatory demyelinating polyneuropathy (CIDP) because of a slower, progressive course, symmetrical and predominantly sensory involvement of legs, predominantly distal slowing of motor conductions, and poorer response to therapy. We studied whether a wide set of electrophysiologic parameters may differentiate these two neuropathies.
METHODS: We reviewed the electrophysiological studies of 10 patients with anti-MAG/SGPG antibodies and 22 with CIDP examining: (1) motor conduction velocity and distal compound muscle action potential amplitude; (2) conduction block (CB) and temporal dispersion; (3) distal motor latency and terminal latency index (TLI); (4) F wave and proximal conduction time; and (5) sensory conduction and occurrence of abnormal median with normal sural sensory potential.
RESULTS: Anti-MAG/SGPG neuropathies showed: (1) more severe involvement of peroneal nerves; (2) more frequent disproportionate distal slowing of motor conductions (TLI< or =0.25) and absent sural potential, and (3) no CB. However 3/22 CIDP patients also had at least two nerves with TLI< or =0.25 and no CB.
CONCLUSIONS: Electrophysiologic findings suggest in anti-MAG/SGPG neuropathy a length-dependent process with a likely centripetal evolution. A disproportionate slowing of conduction in distal segments of motor nerves suggests the diagnosis of anti-MAG/SGPG neuropathy, although it is not pathognomonic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897535     DOI: 10.1016/s1388-2457(02)00011-1

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  7 in total

1.  Peripheral neuropathies in Waldenström's macroglobulinaemia.

Authors:  T Levine; A Pestronk; J Florence; M T Al-Lozi; G Lopate; T Miller; I Ramneantu; W Waheed; M Stambuk; M J Stone; R Choksi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

2.  The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.

Authors:  Christopher J Klein; Joon-Shik Moon; Michelle L Mauermann; Steven R Zeldenrust; Yanhong Wu; Angela Dispenzieri; Peter J Dyck
Journal:  Can J Neurol Sci       Date:  2011-03       Impact factor: 2.104

3.  Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.

Authors:  Sabrina Matà; Stefano Ambrosini; Domenica Saccomanno; Tiziana Biagioli; Marinella Carpo; Aldo Amantini; Fabio Giannini; Alessandro Barilaro; Lucia Toscani; Monica Del Mastio; Giacomo Pietro Comi; Sandro Sorbi
Journal:  Neurol Sci       Date:  2019-10-25       Impact factor: 3.307

4.  Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?

Authors:  Pierre Lozeron; Vincent Ribrag; David Adams; Marion Brisset; Marguerite Vignon; Marine Baron; Marion Malphettes; Marie Theaudin; Bertrand Arnulf; Nathalie Kubis
Journal:  J Neurol       Date:  2016-06-17       Impact factor: 4.849

5.  Entrapment in anti myelin-associated glycoprotein neuropathy.

Authors:  Catharina G Faber; Nicolette C Notermans; John H J Wokke; Hessel Franssen
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

6.  Chronic inflammatory demyelinating polyradiculoneuropathy with ataxia.

Authors:  R C Stockdale; C K Biswas
Journal:  J R Soc Med       Date:  2004-07       Impact factor: 18.000

7.  Rituximab Improves Subclinical Temporal Dispersion of Distal Compound Muscle Action Potential in Anti-MAG/SGPG Neuropathy Associated with Waldenström Macroglobulinemia: A Case Report.

Authors:  Minori Kodaira; Kanji Yamamoto
Journal:  Case Rep Neurol       Date:  2013-02-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.